Imfinzi (durvalumab) continues to demonstrate a sustained survival benefit in patients with inoperable, locally advanced non-small cell lung cancer (NSCLC) who had not progressed after platinum-based chemotherapy and radiation therapy, a four-year analysis shows. Updated findings from the PACIFIC Phase 3 trial (NCT02125461) demonstrate that, at four years, more participants receiving Imfinzi were alive, compared with those on a placebo. In addition, nearly double the number of participants were alive and without signs of disease progression.…
You must be logged in to read/download the full post.
The post Nearly Half of Imfinzi-treated NSCLC Patients Alive After 4 Years, PACIFIC Update Shows appeared first on BioNewsFeeds.